New York, United States, October 13, 2026 /MarketersMEDIA/ -- Ace Therapeutics, a contract research organization specializing in cardiovascular disease research, announced the availability of its expanded suite of custom hypertension animal models. These animal models are designed to support preclinical researchers in investigating hypertension pathogenesis, identifying novel therapeutic targets, and evaluating the efficacy of emerging antihypertensive therapies.

Hypertension remains a leading global health challenge, with complex pathogenesis and strong associations with severe complications including coronary heart disease, diabetes, heart failure, renal disease, and stroke. The development of high-quality, tailored preclinical models is therefore essential for bridging the gap between laboratory research and clinical application. Ace Therapeutics’ hypertension animal models address this need by providing a diverse array of customizable solutions through its dedicated animal model development platform.

Comprehensive Model Categories

Ace Therapeutics’ custom hypertension animal models span three core categories: hereditary/spontaneous hypertension, experimentally induced hypertension, and genetically engineered hypertension. Experimentally induced hypertension includes drug-induced, environment-induced, and surgery-induced models. Each model is developed to align with clients’ specific research objectives, from fundamental pathogenesis studies to late-stage drug efficacy testing.

• Essential Hypertension Models — These heritable models are derived from selective inbreeding over multiple generations and spontaneously develop hypertension as they age. Ace Therapeutics offers proven strains including spontaneously hypertensive rats (SHR), stroke-prone SHR (SHRsp), and Dahl salt-sensitive rats (DSS). Validation follows strain-specific protocols. In SHR and SHRSP, blood pressure begins to rise at approximately 4–6 weeks of age; model success is generally defined as systolic blood pressure (SBP) reaching and maintaining ≥160 mmHg. DSS rats require a high-salt diet for validation.
• Drug-Induced Hypertension Models — Designed for studying hypertension triggered by pharmacological agents, these models utilize compounds such as angiotensin II, L-NAME, and deoxycorticosterone acetate (DOCA), often in combination with salt loading and/or uninephrectomy for DOCA-salt hypertension. Available for Sprague-Dawley and Wistar rats, these models offer faster turnaround times and are validated at an SBP of ≥160 mmHg.
• Environment-Induced Hypertension Models — Recognizing that external factors such as stress, dietary changes, and chronic intermittent hypoxia contribute to clinical hypertension, Ace Therapeutics develops models tailored to these specific triggers using SD and Wistar rats.
• Surgery-Induced Hypertension Models — For studies requiring arterial narrowing, Ace Therapeutics offers procedures such as renal artery stenosis, abdominal aortic constriction, and two-kidney, one-clip (2K1C) placement. These models support multiple species including rats, rabbits, and pigs, each with species-specific validation protocols.
• Genetically Engineered Hypertension Models — Transgenic and knockout models enable precise study of molecular pathways. Ace Therapeutics also offers hereditary hypertensive strains including fawn-hooded hypertensive (FHH) rats, Milan hypertensive strain (MHS) rats, Lyon hypertensive (LH) rats, and Sabra hypertensive (SBH) rats. Validation is performed according to strain- or model-specific protocols; early blood pressure assessment may begin at 4–6 weeks of age for some strains.

For all hypertension models, Ace Therapeutics provides an end-to-end development process that ensures consistency and efficiency. This comprehensive approach encompasses animal sourcing across multiple species, model construction through environmental stress, surgical intervention, or pharmacological induction, and rigorous model evaluation using gold-standard blood pressure testing and ELISA-based biomarker assays.

About Ace Therapeutics

Ace Therapeutics is a contract research organization dedicated to advancing cardiovascular disease research through comprehensive preclinical solutions. It provides cardiovascular disease model development services, biomarker assay services, and biospecimen collection and analysis services for basic research and drug development across a wide spectrum of cardiovascular conditions.

Contact Info:
Name: Daisy Mostert
Email: Send Email
Organization: Ace Therapeutics
Address: Hauppauge, NY 11788, USA
Phone: 1-516-441-0167
Website: https://www.acetherapeutics.com/cardiovascular-diseases/

Release ID: 89206003

In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.